FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Peptides are all anyone wants ...

You’ve probably seen compounding making headlines recently, and not for the right reasons. From so-called “personalized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...

Every investor has heard this quote at least once in their career: “Compound interest is the eighth wonder of the world. He who understands it earns it. He who doesn’t pays it," is a quote often ...

With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory ...

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Pharmaceutical companies in Europe are blocking the sale of drugs used for lethal injection in the U.S. That has states that use the drugs turning to compounding pharmacies to create them. David ...